Sionna Therapeutics FY2024 net loss $61.7M; cash $168M plus $199.6M IPO net proceeds extend runway into 2028

Sionna Therapeutics, Inc.

Net loss Q4 2024 $15.8M, full year $61.7M vs $47.3M in 2023; R&D spend $57.3M.
Cash, equivalents and marketable securities $168.0M as of Dec 2024; excluding $199.6M net IPO proceeds from February 2025.
Upsized IPO raised $219M gross ($199.6M net) in Feb 2025; shares trading on Nasdaq under SION.
Phase 1 MAD dosing completed for SION-451; final MAD cohort for SION-719 planned; topline data expected H1 2025.
Plan to initiate Phase 2a POC trial in CF patients H2 2025 with topline data mid-2026; combination MAD trials also planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.